查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1919334

经皮皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场按产品类型、便携性、安装方式和最终用户划分 - 全球预测 2026-2032 年

Transcutaneous PO2 & PCO2 Monitor Market by Product Type, Portability, Mounting Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场价值为 5.1638 亿美元，预计到 2026 年将成长至 5.6058 亿美元，到 2032 年将达到 8.0369 亿美元，复合年增长率为 6.52%。

关键市场统计数据
基准年 2025 5.1638亿美元
预计年份：2026年 5.6058亿美元
预测年份 2032 8.0369亿美元
复合年增长率 (%) 6.52%

将经皮氧分压和二氧化碳分压监测策略性地应用于经皮发展的临床工作流程和以患者为中心的呼吸护理路径

经皮氧分压和二氧化碳分压监测是一项成熟且不断发展的诊断技术，它将床边生理状态与更广泛的医疗服务目标连结起来。本报告首先将经经皮氧分压（PO2）和二氧化碳分压（PCO2）监测置于现代临床路径中，其中连续、非侵入性的气体评估支持新生儿稳定、重症监护协调、手术全期手术期管理和远端呼吸追踪。虽然脉搏血氧计和动脉血气分析已成为某些诊疗标准，但经皮感测器具有互补的时间分辨率和生理保真度，能够减少有创采样并实现更早的治疗性介入。

技术、监管和医疗服务模式的变革如何融合，重新定义经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测的部署和价值

经经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测领域正因技术和架构的创新而改变。感测器化学的进步、更薄的薄膜设计以及低功耗无线通讯协定的出现，使得设备更加精准且易于部署。同时，软体驱动的分析和云端资料聚合正在拓展单一感测器资料的效用，使其能够用于建立纵向患者记录并提供人群层面的洞察。这些进步共同推动了新型医疗模式的形成，在这种模式下，持续的生理监测能够实现早期疗育和更个人化的治疗调整。

评估 2025 年美国关税如何重塑经经皮监测设备供应商的供应链、筹资策略和产品设计重点。

2025年美国关税政策的变化对经皮监测的供应链和商业策略产生了多方面的影响。特别是，关税影响了感测器组件、电子模组和成品的采购成本，促使製造商和医疗系统采购团队重新评估其供应商布局。因此，一些供应商正在加快供应商多元化进程，并增加对近岸生产能力的投资，以降低关税风险并缩短前置作业时间。

深入了解经皮监测产品类型、便携性、安装方式和最终用户环境如何驱动差异化需求和采用路径

这项細項分析揭示了不同的临床需求和部署环境如何影响经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测的产品开发和商业化重点。按产品类型划分，包括整合双气体检测的组合式监测解决方案、针对二氧化碳趋势优化的专用 PCO2 设备以及专注于氧气评估的专用 PO2 系统。这些差异会影响校准策略、感测器膜的选择以及临床医生在不同护理场景中优先考虑的使用者介面功能。

我们探讨了区域差异，并解释了为什么美洲、欧洲、中东和非洲以及亚太市场都需要独特的实施、分销和支援策略。

区域趋势在塑造经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测的产品需求、监管策略和市场推广方式方面发挥着至关重要的作用。在美洲，许多医疗保健系统优先考虑基于价值的采购，并快速采用已被证实能够减少侵入性手术的技术。这种环境有利于那些能够与更广泛的医疗保健 IT 生态系统集成，并提供可靠的临床证据证明效用的设备。主要国内市场的法规结构也为临床检验和医院采用提供了一致的路径，从而促进了供应商与大型综合医疗保健网络之间的伙伴关係。

透过临床检验、整合服务模式和数据驱动差异化，不断演变经皮监测供应商之间的竞争定位

经经皮监测领域的竞争格局由众多参与者构成，包括成熟的医疗设备製造商、专业感测器开发商和新兴的数位医疗公司。主要企业凭藉其临床检验的深度、强大的分销网络以及将监测数据整合到更广泛的医疗管理系统中的能力而脱颖而出。一些公司优先考虑垂直整合，透过控制感测器的化学成分、电子元件和软体来优化性能并保护智慧财产权。另一些公司则透过建立策略联盟和授权协议来加速市场进入并扩展产品系列。

为製造商和医疗系统提供实际的策略行动，以加速产品应用、降低价值链风险并展现临床和经济价值。

产业领导者若想加速产品普及并保障商业性利润，应将产品开发、监管规划和商业模式与实际临床工作流程相契合。优先考虑互通性和以使用者为中心的设计，确保设备能够整合到各种电子病历环境中，并让临床医生在接受培训后即可轻鬆上手。投资于基于标准的通讯协定和简化的使用者介面，将降低产品普及门槛，并有助于临床医生儘早接受产品。

透明、多维度的研究结合了临床医生访谈、供应商评估和监管分析，提供检验的、可操作的见解。

本分析的研究基础是将与关键相关人员的直接对话与系统性的二手资料研究结合，从而得出严谨且切实可行的结论。主要资讯来源包括对新生儿科、重症监护室、急诊部和手术全期手术期医学等专科的临床医生；来自不同类型医疗系统的采购主管；以及医疗设备製造商和零件供应商的高管进行的深度访谈。这些访谈旨在揭示实际应用中的挑战、临床优先事项和采购决策标准，从而提供有助于解读技术趋势和竞争格局的见解。

本文对经皮监测相关人员而言，是一份简明扼要的策略性结论，它将技术进步、供应链现状和临床重点连结起来。

总之，经皮氧分压（PO2）和二氧化碳分压（PCO2）监测在现代呼吸和重症监护实践中发挥日益重要的作用。技术的进步、数据整合能力的提升以及以服务为导向的商业化模式，正在拓展这些设备发挥临床价值的适用范围。同时，供应链压力和不断变化的监管要求也迫使供应商和采购商采取稳健的筹资策略，并优先考虑高度互通性、以使用者为中心的解决方案。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场（按产品类型划分）

  • 复合监测器
  • PCO2监测
  • 氧分压监测

第九章 行动端经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测市场

  • 携带式的
  • 固定式

第十章 依安装方式经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场

  • 桌面型
  • 壁挂式

第十一章经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场（以最终用户划分）

  • 诊所
    • 门诊手术中心
    • 医生诊所
  • 居家医疗
  • 医院
    • 急诊室
    • 加护病房
    • 新生儿加护病房
    • 手术室

第十二章经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国经经皮氧分压 (PO2) 与二氧化碳分压 (PCO2) 监测仪市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国经皮氧分压 (PO2) 和二氧化碳分压 (PCO2) 监测仪市场

16. 中国经皮氧分压（PO2）及二氧化碳分压（PCO2）监测仪市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bionet Co., Ltd.
  • Contec Medical Systems Co., Ltd.
  • Criticare Systems, Inc.
  • Dragerwerk AG & Co. KGaA
  • Edan Instruments, Inc.
  • Edwards Lifesciences Corporation
  • GE Healthcare Ltd.
  • Masimo Corporation
  • Medtronic plc
  • Mindray Medical International Limited
  • Natus Medical Incorporated
  • NIHON KOHDEN Corporation
  • Nonin Medical, Inc.
  • OSENSA Innovations, Inc.
  • Oximetrix, Inc.
  • Philips Healthcare
  • PULSION Medical Systems SE
  • Radiometer Medical ApS
  • SenTec AG
  • SLE Limited
  • Smiths Medical, Inc.
  • Spacelabs Healthcare, Inc.
  • Toshiba Medical Systems Corporation
Product Code: MRR-F14BA1B341C5

The Transcutaneous PO2 & PCO2 Monitor Market was valued at USD 516.38 million in 2025 and is projected to grow to USD 560.58 million in 2026, with a CAGR of 6.52%, reaching USD 803.69 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 516.38 million
Estimated Year [2026] USD 560.58 million
Forecast Year [2032] USD 803.69 million
CAGR (%) 6.52%

A strategic introduction that situates transcutaneous PO2 and PCO2 monitoring within evolving clinical workflows and patient-centered respiratory care pathways

Transcutaneous monitoring of partial pressures of oxygen and carbon dioxide represents a mature yet evolving diagnostic modality that bridges bedside physiology with broader care delivery objectives. This report opens by situating transcutaneous PO2 and PCO2 monitoring within modern clinical pathways, where continuous, noninvasive gas assessment supports neonatal stabilization, critical care titration, perioperative management, and remote respiratory follow-up. Where pulse oximetry and arterial blood gas sampling have defined certain standards of care, transcutaneous sensors offer complementary temporal resolution and physiologic fidelity that can reduce invasive sampling and enable earlier therapeutic intervention.

As clinical teams confront staffing constraints, heightened demand for neonatal and critical care services, and an increased emphasis on patient-centered outpatient management, transcutaneous monitoring has potential to recalibrate workflows by enabling continuous trending rather than episodic point measurements. Moreover, the device landscape is diversifying along axes of portability, integration, and algorithmic augmentation, which allows these tools to be tailored to specific care settings and patient risk profiles. In practice, these technological shifts are not only technical; they represent changes in clinical decision-making, procurement priorities, and training programs.

Consequently, the introduction frames the subsequent analysis by connecting technical attributes of transcutaneous monitors to operational outcomes such as reduced procedural interventions, improved trend recognition, and potential efficiencies in care delivery. The emphasis is on pragmatic deployment pathways that support adoption across a range of healthcare environments, from highly monitored intensive care units to ambulatory clinics and homecare scenarios.

How technological, regulatory, and care-delivery transformations are converging to redefine deployment and value of transcutaneous PO2 and PCO2 monitoring

The landscape for transcutaneous PO2 and PCO2 monitoring is shifting in ways that are as technological as they are structural. Advances in sensor chemistry, thinner membrane designs, and low-power wireless protocols have enabled devices that are both more accurate and more convenient to deploy. At the same time, software-driven analytics and cloud-enabled data aggregation are extending the utility of single-sensor data into longitudinal patient records and population-level insights. Together, these developments facilitate new models of care where continuous physiologic monitoring informs earlier intervention and more personalized titration of therapy.

In parallel, regulatory expectations and procurement criteria are evolving to emphasize interoperability, cybersecurity, and evidence of clinical utility. Health systems increasingly favor devices that integrate with electronic medical records and adhere to standardized data formats, creating pressure on vendors to prioritize open architectures. Furthermore, reimbursement landscapes and clinical pathways are adapting to favor noninvasive modalities that reduce procedural burden; this is accelerating interest in transcutaneous solutions that can demonstrably lower the frequency of arterial sampling while maintaining diagnostic confidence.

Additionally, workforce dynamics and care-site diversification are important catalysts for change. Staffing shortages and shifts toward ambulatory and home-based care are prompting clinical teams to seek monitoring technologies that support task-shifting and remote supervision. Consequently, the market is moving toward modular product designs, flexible service models, and partnerships that embed monitoring capabilities into broader digital health ecosystems. These transformative shifts highlight a trajectory where clinical value, data integration, and operational flexibility converge to redefine the role of transcutaneous monitoring in contemporary care delivery.

Assessment of how the 2025 United States tariff measures reshaped supply chains, sourcing strategies, and product design priorities across transcutaneous monitoring suppliers

Tariff policy changes enacted in the United States in 2025 have exerted a multifaceted influence on the transcutaneous monitoring supply chain and commercial strategies. Importantly, tariffs affect the economics of sourcing sensor components, electronic modules, and finished devices, prompting manufacturers and health system procurement teams to reassess supplier footprints. As a result, some vendors have accelerated diversification of their supplier base and increased investment in nearshore production capabilities to mitigate tariff exposure and compress lead times.

At the same time, higher import costs have incentivized product rationalization and modular design approaches that reduce reliance on tariff-exposed components. Vendors are prioritizing local assembly of subassemblies and reconfigurable platforms that can be tailored to regional regulatory requirements without reinventing core technology. For healthcare providers, these supply chain adjustments have manifested as sporadic price adjustments, longer qualification lead times for new suppliers, and an elevated emphasis on total cost of ownership during procurement deliberations.

Moreover, tariffs have amplified the importance of regulatory agility and supply chain transparency. Organizations are placing greater emphasis on traceability, dual-sourcing strategies, and contractual clauses that allocate currency and trade risk. Consequently, strategic alliances and contract manufacturing relationships have taken on new relevance as pathways to preserve margin and ensure continuity of supply. In sum, the cumulative effect of tariff actions has been to accelerate risk mitigation efforts, to shift some sourcing toward regional partners, and to catalyze design decisions that reduce trade exposure while maintaining clinical performance.

Insights into how product types, portability, mounting options, and end-user environments drive differentiated requirements and adoption pathways for transcutaneous monitors

Segmentation analysis reveals how divergent clinical needs and deployment contexts shape product development and commercialization priorities for transcutaneous PO2 and PCO2 monitoring. Based on product type, the landscape includes Combined Monitor solutions that integrate dual-gas sensing, PCO2-focused devices optimized for carbon dioxide trends, and PO2-dedicated systems tuned for oxygen assessment. These distinctions influence calibration strategies, sensor membrane selection, and user-interface features that clinicians favor in different care scenarios.

Turning to portability, the market is studied across Portable devices that support point-of-care flexibility and Stationary platforms intended for continuous bedside monitoring. Portability considerations drive battery management, wireless connectivity choices, and wearable ergonomics, whereas stationary systems prioritize integration with bedside infrastructure and advanced alarm workflows. Equally, mounting type differentiates between Benchtop instruments suited to clinical workstation environments and Wall Mounted configurations designed to conserve surface space and centralize monitoring in high-acuity units.

End user segmentation further clarifies clinical adoption pathways. The market is examined across Clinic settings where ambulatory surgical centers and physician offices demand compact, user-friendly devices; Homecare contexts that require simplified interfaces, extended sensor life, and robust remote connectivity; and Hospital environments where emergency departments, intensive care units, neonatal intensive care units, and operating rooms demand high-fidelity measurements, rapid calibration, and seamless integration with existing monitoring systems. Through these segmentation lenses, developers and purchasers can align product roadmaps, training programs, and service models with specific clinical workflows and user expectations.

A nuanced regional view that explains how Americas, Europe Middle East & Africa, and Asia-Pacific markets demand bespoke strategies for adoption, distribution, and support

Regional dynamics play a decisive role in shaping product demand, regulatory strategy, and go-to-market approaches for transcutaneous PO2 and PCO2 monitoring. Across the Americas, many health systems emphasize value-based procurement and rapid adoption of technologies that demonstrably reduce invasive procedures; this environment favors devices that can integrate with broad health IT ecosystems and that provide robust clinical evidence for utility. Regulatory frameworks in key national markets also create consistent pathways for clinical validation and hospital adoption, encouraging partnerships between vendors and large integrated delivery networks.

In Europe, Middle East & Africa, fragmentation in regulatory regimes and heterogeneous procurement practices result in a mosaic of adoption patterns. Some markets prioritize cost-containment and local manufacturing partnerships, while others emphasize advanced clinical capabilities and interoperability. Consequently, vendors often deploy region-specific strategies that combine direct sales in high-income European markets with distributor partnerships and localized service models in other parts of the region. This tiered approach enables alignment with variable reimbursement environments and infrastructural maturity.

Asia-Pacific is characterized by rapid technological uptake in several advanced healthcare systems alongside a growing number of emerging markets seeking scalable, low-cost monitoring solutions. In many countries, the confluence of expanding neonatal care capacity and investment in acute care facilities creates demand for both portable and stationary transcutaneous systems. Vendors targeting this region benefit from flexible pricing models, local manufacturing partnerships, and regulatory strategies that accommodate accelerated evaluation while ensuring adherence to international performance standards. Collectively, these regional nuances inform prioritization of product development, distribution networks, and post-sale support models.

How competitive positioning is evolving through clinical validation, integrated service models, and data-driven differentiation among transcutaneous monitoring vendors

Competitive dynamics within the transcutaneous monitoring space are shaped by a mix of established medical device manufacturers, specialized sensor developers, and emerging digital-health entrants. Leading players differentiate through depth of clinical validation, strength of distribution networks, and the ability to integrate monitoring data into broader care management systems. Some companies have prioritized vertical integration-controlling sensor chemistry, electronics, and software-to optimize performance and to protect intellectual property, while others have formed strategic partnerships or licensing agreements to accelerate market entry and extend their product portfolios.

In addition to product features, service models and lifecycle support increasingly determine competitive advantage. Organizations that offer modular maintenance contracts, on-site training, and remote calibration services reduce operational friction for hospitals and clinics, thereby improving user retention. Furthermore, companies that invest in interoperability and secure data-sharing capabilities position themselves favorably as healthcare organizations look to consolidate monitoring data into enterprise analytics platforms.

Finally, new entrants applying artificial intelligence and predictive analytics to monitoring streams are reshaping expectations about what continuous physiological data can deliver. These capabilities enhance early warning systems and clinical decision support, creating additional differentiation beyond hardware specifications. As a result, collaboration between device makers, software vendors, and care providers has become central to competitive strategy, and market leadership increasingly depends on the ability to deliver validated clinical outcomes rather than hardware alone.

Practical strategic actions for manufacturers and health systems to accelerate adoption, de-risk supply chains, and demonstrate clinical and economic value

Industry leaders seeking to accelerate adoption and to protect commercial margins should align product development, regulatory planning, and commercial models with real-world clinical workflows. First, prioritize interoperability and user-centered design to ensure devices can be incorporated into diverse electronic health record environments and that clinicians can deploy them with minimal training. Investments in standards-based communication protocols and streamlined user interfaces reduce implementation friction and support faster clinician acceptance.

Second, develop flexible manufacturing and supply chain strategies that mitigate trade exposure and enable rapid scaling. Nearshoring assembly of critical subcomponents, qualifying multiple suppliers for sensor membranes and electronic modules, and negotiating resilient service contracts will reduce operational risk. Third, frame value propositions around clinical outcomes and total cost of care rather than unit price alone. Collaborative pilot studies with high-volume neonatal and critical care centers can generate the evidence needed to support procurement decisions and payer conversations.

Finally, embrace service-led commercialization models that incorporate remote calibration, predictive maintenance, and outcome analytics into recurring revenue streams. These models not only strengthen customer relationships but also provide ongoing data that can inform iterative product improvements. By pursuing these actions in a coordinated manner, leaders can translate technological capability into durable market presence and measurable improvements in patient care.

A transparent, multi-method research approach combining clinician interviews, supplier assessments, and regulatory analysis to produce validated and actionable insights

The research underpinning this analysis combines primary stakeholder engagement with structured secondary review to ensure rigorous, actionable conclusions. Primary inputs include in-depth interviews with clinicians across neonatal, intensive care, emergency, and perioperative specialties, procurement leaders from diverse health system types, and executives from device manufacturers and component suppliers. These conversations were designed to surface real-world deployment challenges, clinical priorities, and procurement decision criteria, and they informed interpretation of technical trends and competitive dynamics.

Secondary analysis integrated regulatory guidance documents, device performance literature, and credible policy reporting to contextualize operational and supply chain developments. In addition, comparative device feature mapping and supplier capability assessments were performed to identify differentiators across product portfolios. The methodology emphasizes triangulation: thematic insights derived from interviews were cross-checked against secondary sources and supplier disclosures to validate claims and to refine recommendations.

Throughout the process, attention was paid to minimizing bias through balanced sampling across geographies and end-user types, and by documenting assumptions that underpin interpretive judgments. The resulting framework supports both strategic planning and tactical decision-making by highlighting where clinical needs intersect with technological possibilities and commercial realities.

A concise synthesis that ties technological advances, supply chain realities, and clinical priorities into strategic conclusions for stakeholders in transcutaneous monitoring

In conclusion, transcutaneous PO2 and PCO2 monitoring occupies an increasingly important niche within contemporary respiratory and critical care practice. Technological refinements, enhanced data integration, and service-oriented commercialization approaches are expanding the contexts in which these devices can add clinical value. At the same time, supply chain pressures and evolving regulatory expectations compel vendors and purchasers to adopt resilient sourcing strategies and to prioritize interoperable, user-centered solutions.

Looking ahead, stakeholders that align product design with demonstrable clinical outcomes and that adopt flexible commercial models will be best positioned to capture opportunities across neonatal care, intensive care, ambulatory settings, and homecare. Strategic partnerships that marry hardware expertise with analytics and integration capabilities will further accelerate adoption by simplifying implementation for busy clinical teams. Ultimately, the most impactful advances will be those that translate continuous physiologic data into clearer, earlier clinical decisions and measurable improvements in patient experience.

This synthesis is intended to inform leaders across clinical, commercial, and regulatory functions as they define roadmaps, prioritize investments, and negotiate procurement strategies in a rapidly evolving landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcutaneous PO2 & PCO2 Monitor Market, by Product Type

  • 8.1. Combined Monitor
  • 8.2. PCO2 Monitor
  • 8.3. PO2 Monitor

9. Transcutaneous PO2 & PCO2 Monitor Market, by Portability

  • 9.1. Portable
  • 9.2. Stationary

10. Transcutaneous PO2 & PCO2 Monitor Market, by Mounting Type

  • 10.1. Benchtop
  • 10.2. Wall Mounted

11. Transcutaneous PO2 & PCO2 Monitor Market, by End User

  • 11.1. Clinic
    • 11.1.1. Ambulatory Surgical Center
    • 11.1.2. Physician Office
  • 11.2. Homecare
  • 11.3. Hospital
    • 11.3.1. Emergency Department
    • 11.3.2. Intensive Care Unit
    • 11.3.3. Neonatal Intensive Care Unit
    • 11.3.4. Operating Room

12. Transcutaneous PO2 & PCO2 Monitor Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transcutaneous PO2 & PCO2 Monitor Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transcutaneous PO2 & PCO2 Monitor Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transcutaneous PO2 & PCO2 Monitor Market

16. China Transcutaneous PO2 & PCO2 Monitor Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bionet Co., Ltd.
  • 17.6. Contec Medical Systems Co., Ltd.
  • 17.7. Criticare Systems, Inc.
  • 17.8. Dragerwerk AG & Co. KGaA
  • 17.9. Edan Instruments, Inc.
  • 17.10. Edwards Lifesciences Corporation
  • 17.11. GE Healthcare Ltd.
  • 17.12. Masimo Corporation
  • 17.13. Medtronic plc
  • 17.14. Mindray Medical International Limited
  • 17.15. Natus Medical Incorporated
  • 17.16. NIHON KOHDEN Corporation
  • 17.17. Nonin Medical, Inc.
  • 17.18. OSENSA Innovations, Inc.
  • 17.19. Oximetrix, Inc.
  • 17.20. Philips Healthcare
  • 17.21. PULSION Medical Systems SE
  • 17.22. Radiometer Medical ApS
  • 17.23. SenTec AG
  • 17.24. SLE Limited
  • 17.25. Smiths Medical, Inc.
  • 17.26. Spacelabs Healthcare, Inc.
  • 17.27. Toshiba Medical Systems Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COMBINED MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COMBINED MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COMBINED MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PCO2 MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PCO2 MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PCO2 MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PO2 MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PO2 MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PO2 MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY STATIONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY STATIONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY STATIONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY WALL MOUNTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY WALL MOUNTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY WALL MOUNTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PHYSICIAN OFFICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PHYSICIAN OFFICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PHYSICIAN OFFICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY NEONATAL INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY NEONATAL INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY NEONATAL INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY OPERATING ROOM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY OPERATING ROOM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY OPERATING ROOM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 124. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 127. GCC TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 142. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 145. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 148. G7 TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 149. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 152. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 155. NATO TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY MOUNTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA TRANSCUTANEOUS PO2 & PCO2 MONITOR MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)